Literature DB >> 17503082

Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion.

Keiko Nakazato1, Chol Kim, Katsuyuki Terajima, Satoru Murata, Hitoshi Fujitani, Kazuhiro Nakanishi, Hiroyuki Tajima, Tatsuo Kumazaki, Atsuhiro Sakamoto.   

Abstract

PURPOSE: Negative-balance isolated pelvic perfusion (NIPP) is used to administer high doses of anticancer drugs such as cisplatin to patients with advanced cancer of the pelvic region. Although the drugs are intended to be specifically delivered to the pelvis, their leakage into the systemic circulation can cause acute renal failure. This study examines the loading volume required for preservation of renal function during anesthesia of NIPP.
METHODS: Pelvic cancer patients were assigned to NIPP according to its enrollment criteria. Patients with heart failure, uncontrollable hypertension, renal failure, pulmonary disease or contraindication for the contrast media were excluded. We compared the current anesthesia management regime with a previous protocol, with regard to the loading volume and renal function as assessed by the calculated glomerular filtration rate (GFR). The correlation between the total loading volume and the GFR ratio (GFR after NIPP/GFR before NIPP) was evaluated to define adequate volume loading.
RESULTS: The GFR ratios were 0.86 +/- 0.29 and 1.12 +/- 0.25 for the previous and current procedures, respectively. The regression line showed that a minimum loading volume of 28.8 ml kg(-1) h(-1) was required to maintain a GFR ratio of > or =1.
CONCLUSIONS: A large volume infusion preserves the GFR despite high-dose cisplatin administration by NIPP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503082     DOI: 10.1007/s00432-007-0217-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Cisplatin nephrotoxicity: experimental and clinical studies.

Authors:  G Daugaard
Journal:  Dan Med Bull       Date:  1990-02

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model.

Authors:  Satoru Murata; Hiroyuki Tajima; Gen-ichi Kusakai; Tatsuo Kumazaki; Yutaka Abe; Shiro Onozawa; Yasushige Komada; Yukihiro Kondo; Ryoji Kimata; Seiichiro Himeno; Mitsuo Satake
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

6.  Hemodynamic changes during a new procedure for regional chemotherapy involving occlusion of the thoracic aorta and inferior vena cava.

Authors:  H Berkenstadt; G Ben-Ari; A Perel
Journal:  J Clin Anesth       Date:  1998-12       Impact factor: 9.452

7.  Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.

Authors:  M Al-Sarraf; W Fletcher; N Oishi; R Pugh; J S Hewlett; L Balducci; J McCracken; F Padilla
Journal:  Cancer Treat Rep       Date:  1982-01

8.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  Cisplatin nephrotoxicity.

Authors:  Istvan Arany; Robert L Safirstein
Journal:  Semin Nephrol       Date:  2003-09       Impact factor: 5.299

Review 10.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

View more
  2 in total

1.  The negative-balance isolated pelvic perfusion method using ultrahigh-dose cisplatin for invasive bladder cancer with poor risk.

Authors:  Ryoji Kimata; Yukihiro Kondo; Kaoru Nemoto; Satoru Murata; Tatsuo Kumazaki
Journal:  Int J Clin Oncol       Date:  2010-04-21       Impact factor: 3.402

2.  Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment.

Authors:  Rodney J Hunter; Makala B Pace; Kimberly A Burns; Catherine C Burke; Deborah A Gonzales; Nicki F Webb; Charles F Levenback; Anuja Jhingran; Crystal Parker; Mark F Munsell; Judith A Smith
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.